Literature DB >> 3315456

The frequency of corneal dystrophies requiring keratoplasty in Europe and the U.S.A.

G K Lang1, G O Naumann.   

Abstract

A clinical and pathologic review of 1,335 corneal buttons received from 1964 to 1985 revealed 185 (13.9%) corneal dystrophies treated with keratoplasty. Fuch's endothelial dystrophy accounted for 132 (9.9%), occurring in females 80% of the time. Corneal dystrophies other than Fuchs' accounted for 53 cases (4.0%). Among the latter, the frequencies varied; 38% were granular, 30% were macular, and 19% were lattice dystrophies. The overall prevalence in series from Los Angeles and Baltimore is the same. However, there is a striking difference in the distribution of the frequencies of non-Fuchs' dystrophies. In the Erlangen series, granular dystrophy dominates (38%), while it is rare in the Baltimore series (4%); the reverse is true for lattice dystrophy (Erlangen 19%; Baltimore 37%), while macular dystrophy rates are similar.

Entities:  

Mesh:

Year:  1987        PMID: 3315456     DOI: 10.1097/00003226-198706030-00011

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  4 in total

1.  The association of Fuchs's corneal endothelial dystrophy with axial hypermetropia, shallow anterior chamber, and angle closure glaucoma.

Authors:  J F Pitts; J L Jay
Journal:  Br J Ophthalmol       Date:  1990-10       Impact factor: 4.638

2.  Outcomes of penetrating keratoplasty for macular corneal dystrophy.

Authors:  Farid Karimian; Ali-Reza Baradaran-Rafii; Sepehr Feizi; Mohammad Zare; Mohammad-Reza Jafarinasab; Mohammad-Ali Javadi; S Ali Mirdehghan; Bahram Einollahi
Journal:  J Ophthalmic Vis Res       Date:  2009-01

3.  Prevalence and histopathological characteristics of corneal stromal dystrophies in Saudi Arabia.

Authors:  Sultan Alzuhairy; Hind M Alkatan; Ali A Al-Rajhi
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Apr-Jun

4.  Proliferation of Human Corneal Endothelia in Organ Culture Stimulated by Wounding and the Engineered Human Fibroblast Growth Factor 1 Derivative TTHX1114.

Authors:  David Eveleth; Sarah Pizzuto; Jessica Weant; Jennifer Jenkins-Eveleth; Ralph A Bradshaw
Journal:  J Ocul Pharmacol Ther       Date:  2020-07-28       Impact factor: 2.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.